Evercore ISI Group analyst Josh Schimmer downgrades Ventyx Biosciences (NASDAQ:VTYX) from Outperform to In-Line and lowers the price target from $43 to $5.
Evercore ISI Group Downgrades Ventyx Biosciences to In-Line, Lowers Price Target to $5
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.